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Abstract: Breast cancer has a high incidence worldwide. The results of substantial studis reveal 
that inflammation plays an important role in the initiation, development, and aggressiveness 
of many malignancies. The use of celecoxib, a novel NSAID, is repetitively associated with 
the reduced risk of the occurrence and progression of a number of types of cancer, particularly 
breast cancer. This observation is also substantiated by various meta-analyses. Clinical trials 
have been implemented on integration treatment of celecoxib and shown encouraging results. 
Celecoxib could be treated as a potential candidate for antitumor agent. There are, nonetheless, 
some unaddressed questions concerning the precise mechanism underlying the anticancer effect 
of celecoxib as well as its activity against different types of cancer. In this review, we discuss 
different mechanisms of anticancer effect of celecoxib as well as preclinical/clinical results 
signifying this beneficial effect.
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Introduction
Breast cancer (BC) is the most frequent cancer in women, the second most common 
cancer worldwide, and the second primary cause of cancer-related deaths.1 One in eight 
women who live to age 85 years will develop BC over the course of their lifetime.2 Previ-
ous studies suggest that inflammation is associated with cancer, and a robust correlation 
exists between the manifestation of inflammation and the progress of precancerous 
lesions at a number of anatomic sites.3 On the other hand, cancer cells might exploit 
components of the inflammatory process to induce angiogenesis, inhibit apoptosis, 
and enhance proliferation, migration, and metastasis,4 such as NF-κB, cytokines or 
cytokine receptors, chemokines or chemokine receptors, fibroblast growth factor or 
receptor (FGF or FGFR), and vascular endothelial growth factor (VEGF). Increasing 
evidence demonstrates the key role of chronic inflammation markers in increased BC 
risk5; for example, a meta-analysis suggested a significant dose–response correlation 
for C-reactive protein (CRP) with BC risk.6 The pro-inflammatory cytokines, such as 
interleukin (IL)-6 and tumor necrosis factor (TNF)-α, induce BC cells to penetrate 
the blood vessels, contributing to metastasis.7
Owing to its significant pro-tumor effects, inflammation has become a promising 
target for cancer prevention and treatment. Among various inflammatory factors, 
cyclooxygenase 2 (COX-2) is the most commonly studied anti-inflammatory/anti-
cancer target.8,9 Unlike COX-1, COX-2 is undetectable in normal breast tissue, but 
in tumor tissue, it overexpresses by 40%,10 and in ductal carcinoma in situ (DCIS) it 
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overexpresses by approximately 80%.11 The overexpression of 
COX-2 has been reported in different tumor cells and neovas-
cular endothelial cells.12 The overexpressed COX-2 converts 
arachidonic acid (AA) into prostaglandin E2 (PGE2),13 which 
promotes BC progression through different mechanisms, for 
instance, suppression of antitumor immunity,14 promotion of 
invasiveness,15 migration,15 stem-like cell (SLC) formation,16 
angiogenesis,17 and lymphangiogenesis.18
Over 20 years ago, NSAIDs were reported to have 
anti-colon cancer effects.19 Abundant epidemiological and 
preclinical/clinical studies demonstrated that celecoxib, a 
specific COX-2 inhibitor, was related to suppression of cancer 
cell proliferation and decrease in cancer incidents. In this 
article, different mechanisms underlying anticancer effect 
of celecoxib as well as preclinical/clinical results signifying 
this beneficial effect are discussed.
Celecoxib and BC
Celecoxib is the international nonproprietary name of 
4-[5-(4-methylphenyl)–3-(trifluoromethyl)-1H-pyrazol-1-yl] 
benzenesulfonamide, a COX-2-selective NSAID. Its oral 
capsule form was initially approved by US Food and Drug 
Administration (FDA) and marketed by Pfizer, Inc. (New 
York, NY, USA) in 1999. As a selective COX-2 inhibitor, 
celecoxib is used as an analgesic, anti-inflammatory, and 
antipyretic drug. Numerous preclinical evidence suggests 
that celecoxib may provide a strong chemopreventive activ-
ity against BC. Celecoxib treatment (500–1,500 mg/kg diet) 
can significantly decrease incidence, multiplicity, and tumor 
volume in several animal models of BC.20,21 In addition, 
metastasis to the lung and brain could also be prevented.22,23 
Besides preclinical studies, clinical trials also showed posi-
tive results. Two case–control studies, including 32324 and 
18,36825 BC cases, respectively, illustrated that a standard 
dose intake of celecoxib (200 mg/day) for more than 12 
months was associated with significant reduced risk of BC. 
However, in these studies, OR was different,25 and this might 
be caused by a longer duration of drug intake in the former 
study (more than 2 years vs more than 1 year).
Mechanisms of celecoxib’s 
antitumor action
In spite of the encouraging efficacy mentioned earlier, the 
mechanisms of celecoxib’s antitumor action still need to be 
explored. COX-2 plays an important role in tumorigenesis 
and development. Thus, celecoxib, as a selective COX-2 
inhibitor, is believed to have several potential antitumor 
mechanisms, including inhibition of proliferation,  induction 
of apoptosis, immunoregulation, regulation of tumor micro-
environment, antiangiogenic effect, and resensitization of 
other antitumor drugs. Meanwhile, COX-2-independent 
pathways also contribute to the antitumor effect of celecoxib.
inhibition of proliferation
Celecoxib represses the proliferation of BC cells in vitro 
and also prevents the incidence of BC chemically induced 
by 7,12-dimethylben anthracene (DMBA) in rats. Thus, 
celecoxib shows an anticancer activity and seems to be 
effective in anticancer treatment.26 Bocca et al27 assessed 
the antiproliferative activity of celecoxib on human BC cells 
with different COX-2 expression levels. Celecoxib treatment 
induces a robust inhibition of cell growth in estrogen receptor 
(ER)α (+) MCF-7 cells, which is accompanied by a decrease 
in expression and activation of aromatase and ERα. The 
related mechanism may involve ERK and Akt inhibition as 
well as induction of PP2A and PTEN. In this cell line, cele-
coxib shows only weak effect on COX-2 level. In contrast, in 
ERα (–) MDA-MB-231 cells, celecoxib induces a striking 
suppression of COX-2, which is associated with a decrease 
in aromatase expression and cell proliferation. These results 
imply that celecoxib may exert antiproliferative activity in 
BC cells through COX-2-dependent or COX-2-independent 
pathways. A study identifying transcriptional changes in 
BC tissues of patients treated with celecoxib suggested 
that short-term COX-2 inhibition by the drug stimulates 
transcriptional programs that facilitate antitumor activity 
in primary BC tissue. The influence on proliferation-related 
genes is reflected by a decrease in Ki-67 (+) cells.28 Basu 
et al29 explored the mechanisms by which celecoxib affects 
tumor growth of two human BC cell lines such as MDA-
MB-231 (highly invasive) and MDA-MB-468 (moderately 
invasive). They demonstrated that the distinct molecular 
mechanisms of celecoxib-induced growth suppression 
depend on the expression level of COX-2 and invasiveness 
in different human BC cell lines. The studies suggest that 
COX-2 plays an important role not only in the cancer cell 
growth but also in activating the angiogenic pathway via 
modulating levels of VEGF. Taken together, these results 
provide a theoretical and experimental basis for the clinical 
anticancer effect of celecoxib.
induction of apoptosis
Apoptosis is an evolutionary conserved programmed cellular 
suicide mechanism that is vital for tissue homeostasis in 
multicellular organisms. It also causes the cytotoxic effects in 
response to standard genotoxic chemotherapy/radiotherapy. 
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Intriguingly, some researchers found that the tumor growth 
inhibition effect of celecoxib was mainly caused by induc-
ing apoptosis30 rather than disturbing cell proliferation.31 
Celecoxib-resistant cell lines with COX-2 overexpression32 
exhibit a reduced level of Bax, a pro-apoptosis protein, and 
increased levels of anti-apoptosis proteins such as Bcl-2 or 
Bcl-xL. COX-2 knockdown by its specific siRNA signifi-
cantly decreases clonogenicity and levels of Bcl-xL and Bcl-2 
in these cells. In MDA-MB-23129,30 and MCF-7 cell lines,33 
celecoxib induces apoptosis by decreasing phosphorylation 
of Akt, then increasing the expression of Bax and activation 
of caspase 3 and caspase 7. Wang et al34 showed that cele-
coxib induces apoptosis of the BC cell line, MDA-MB-231, 
by inhibiting the NF-κB pathway. Another mechanism 
of celecoxib-induced apoptosis in most cellular systems 
involves p53-independent mitochondrial apoptosis pathway, 
which is COX-2 independent and could not be inhibited by 
the overexpression of Bcl-2.35,36
Some studies suggest that the antineoplastic effects of 
celecoxib are attributed to its unspecific inhibitory actions on 
β-catenin signaling,37,38 which is a fundamental component of 
the canonical Wnt pathway. Overactivation of Wnt/β-catenin 
signaling is associated with the progression of different types 
of cancer and promotion of cancer cell growth, survival, and 
malignant phenotype. Furthermore, recent studies suggest 
that Wnt/β-catenin signaling plays an important role in the 
modulation of cancer stem cells.39,40 GSK-3β phosphory-
lates and marks β-catenin for ubiquitination and succeeding 
proteasomal degradation. Binding of Wnt ligands to their 
receptors initiates a signaling cascade that averts GSK-3β 
from tagging β-catenin for degradation, leading to its accu-
mulation, translocation to the nucleus, binding to the T cell 
factor (TCF) family of transcription factors, and activation 
of Wnt target gene expression. Celecoxib treatment induces 
GSK-3β dephosphorylation, contributing to β-catenin 
phosphorylation induced by GSK-3β and suppression of the 
Wnt/β-catenin-dependent gene transcription, for example, 
c-Myc or cyclin D1, COX-2, and VEGF.38,41 It is noteworthy 
that GSK-3β is a direct downstream target of Akt/PKB and 
activated Akt/PKB phosphorylates and consequently inac-
tivates GSK-3β. Hence, celecoxib inhibition of Akt/PKB 
might at least partly be responsible for the reduction in the 
β-catenin levels.
Survivin is an “inhibitor of apoptosis” (IAP) protein 
that also functions as a mitotic regulator essential for cell 
 division.42 It represses apoptosis through hindering the activa-
tion of caspases. Intriguingly, celecoxib treatment downregu-
lates survivin levels of cancer cells in vitro and in vivo.43–47 
The degree of survivin inhibition of celecoxib correlates 
with its efficacy to impede cancer cell growth and to promote 
apoptosis among different types of cancer cells. Since pros-
taglandins elevate survivin expression, the downregulation 
of survivin may be partly attributable to celecoxib-induced 
suppression of COX-2.48 In view of the role played by survivin 
in apoptosis resistance of cancer cells, the inhibitory effects 
of celecoxib on this protein might be particularly relevant to 
its use in anticancer treatment.49,50 Whether the induction of 
apoptosis leads to clinical benefits is still debatable. A study 
showed that celecoxib increased apoptosis and reduced the 
levels of PG and VEGF expression.51 However, this effect 
could not postpone tumor appearance and reduce tumor 
progression and development.
immunoregulation
A thorny problem in the process of treating tumors is a 
repressed cell-mediated immunity, characterized by the 
failure of immune effector cells to induce effective antitumor 
responses. CD4+ or CD8+ T cells were mostly involved in 
local tumor suppression, while natural killer (NK) cells were 
involved in tumor metastasis.52 Immunosuppressive factors, 
produced by the tumor, cause this problem according to 
tolerance. COX-2 plays an important role in BC immune 
escape. PGE2 has a series of adverse effects on the immune 
response to tumors in the body, for example, negatively 
influencing the activity of T/B lymphocytes, NK cells, and 
dendritic cells, reducing TNF-α synthesis and increasing the 
activity of immunosuppressive IL-10.53 These unfavorable 
effects ablate the effectiveness of host defenses in monitor-
ing and eliminating malignant cells, thus resulting in their 
unrestrained proliferation.54 Previous studies demonstrate that 
the reduced expression of COX-2 in BC cells promotes tissue 
infiltration of cytotoxic T lymphocytes (CD8+), implying a 
role of COX-2 in immunosuppression. COX-2 inhibitors 
such as celecoxib regulate antitumor immunity in local and 
metastasis BC individually.55 In addition, the application 
of celecoxib in human BCs prompts an increased number 
of immune cells in the tumor microenvironment.54 A study 
by Gallouet et al56 demonstrated that follicular lymphoma 
stromal cells release great amounts of PGE2. This produc-
tion can be abolished by celecoxib treatment that targets the 
COX-2 isoenzyme associated with PGE2 synthesis. Interest-
ingly, they also found that celecoxib promotes apoptosis in 
primary follicular lymphoma B cells cocultured with stromal 
cells, nonetheless, independently of the PGE2/COX-2 axis.
Substantial studies suggested that celecoxib might 
switch the function of immune cells to a more tumor-killing 
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 phenotype via impeding tumors from releasing prostaglan-
dins and via hindering COX activity in immune effector cells. 
Lang et al57 suggested that cancer cells suppress the physi-
ological function of immune cells and that celecoxib, to a 
certain extent, recovers this function. These results deliver an 
in-depth understanding of the anticancer effect of celecoxib 
and support its prophylactic use in high-risk patients. In a 
study evaluating the influence of celecoxib administration on 
tumor-infiltrating lymphocyte (TIL) subsets (CD3[+]CD4[+]
CD8[+]CD25[+] and T cell receptor [TCR]-zeta-expressing 
cells) and tryptase(+) mast cells in human cervical cancers, 
Ferrandina et al58 provided the first evidence that this drug 
can restore zeta expression by TIL in primary cervical can-
cers. Overall, these results suggest that a positive regulation 
of immune function might serve as a crucial mechanism 
underlying the antitumor effect of celecoxib.
Regulation of tumor microenvironment
During chronic inflammation, pro-inflammatory molecules 
including cytokines, ROS, NF-κB, and inducible nitric oxide 
synthase (iNOS) are increased and provide an advantageous 
microenvironment for cancer cell growth. Therefore, inflam-
mation might result in the initiation of cancer and provide 
the suitable environment to support tumor growth.59 The 
tumor microenvironment consists of a variety of cell and 
molecular components, such as matrix metalloproteinases 
(MMPs) and tissue inhibitors of metalloproteinase (TIMP)-1. 
Tumor microenvironment has profound impacts on tumor 
cell proliferation, migration, and apoptosis.60,61 Celecoxib 
inhibits 12-O-tetradecanoyl phorbol-13-acetate (TPA)-
induced MMP-9 expression in a dose-dependent manner by 
increasing the activity of TIMP-1.62,63
The stimulation of constitutive expression of COX-2 is 
a crucial factor in the tumorigenic process. Various key risk 
factors associated with cancer causativeness are capable of 
stimulating COX-2. These factors comprise certain essen-
tial dietary fatty acids, nicotine and its metabolites, growth 
factors, infectious agents, hypoxia, hormones, ultraviolet 
B, and free radicals; oncogenic proteins; and endotoxins; 
etc.64–67 Some microenvironmental stimuli, for example, 
bacterial lipopolysaccharides, TNF, and by-products of 
protein synthesis and degradation, also induce constitutive 
COX-2 expression. In addition, because the COX-2 gene 
contains various promoter binding sites, nuclear transcrip-
tion factors including NF-κβ or NF-IL6 might also mediate 
its upregulation.68 Genetic induction of COX-2 in BC cells 
triggers local constitutive estrogen synthesis through activat-
ing the promoter II region of the aromatase gene (CYP-19) 
in adjacent fat and muscle cells.69 Terry et al70 revealed a 
vital relationship between COX-2 overexpression and mam-
mary tumorigenesis induced by estrogen. Hence, COX-2 
tumorigenesis seems to involve synergistic interactions 
between many microenvironmental and genetic cofactors. 
Accordingly, recent studies suggested that regular use of 
aspirin and other coxibs has noteworthy therapeutic impact 
in cancer patients.71,72 Expression of COX-2 can also be 
increased by large amount of collagen, which contributes 
to high breast density73 and growing incidence of BC.74,75 
This effect can be inhibited by celecoxib through reducing 
overall collagen deposition and the levels of COX-2, PGE2, 
and Ki-67 expression.76
Tumor-associated macrophages are associated with can-
cer cell survival. In a microenvironment study of BC cells, 
Li et al77 demonstrated that COX-2 is plentifully expressed 
in breast tumor-associated macrophages, which is associated 
with poor prognosis in BC patients. Their studies suggested 
that COX-2 serves as an important cancer-promoting fac-
tor through prompting a positive feedback loop between 
macrophages and BC cells. Apparently, COX-2 inhibitor, 
celecoxib, is favorable in disturbing this feedback loop in 
the cancer microenvironment. Accordingly, COX-2 can be 
exploited as a target for BC prevention and therapy. These 
findings provide solid molecular evidence to support the anti-
BC effect of celecoxib, which has potential to raise positive 
expectations for clinical use.
Antiangiogenic effect
Angiogenesis refers to the generation of new blood vessels 
through the extension of preexisting vasculature. It is modu-
lated by an equilibrium between the pro- and antiangiogenic 
factors. During tumorigenesis, the role of pro-angiogenic 
factors exceeds that of their counterpart and triggers the 
growth of new capillaries to supply more blood flow and 
overcome hypoxia inside the cancer microenvironment, 
leading to tumor growth and metastasis. At the molecular 
level, one of the mechanisms underlying COX-2-dependent 
neoplastic initiation and development in BC involves its 
proangiogenic activity.78,79 Actually, COX-2 activates MMPs 
in an intricate mechanism involving NF-κB. This protein 
also promotes endothelial migration by thromboxane A2 
(TXA2).78,80 Moreover, the augmented activity of COX-2 
contributes to the release of proangiogenic factors by 
epithelial and endothelial neoplastic cells, fibroblasts, and 
macrophages.80,81 In detail, COX-2-dependent angiogenesis 
begins with the formation of proangiogenic prostaglandins 
(primarily PGE2) by tumor cells, which enhances the levels 
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of VEGF and bFGF. VEGF directly induces COX-2 in ECs, 
while bFGF induces COX-2 in fibroblasts to synthesize PGs, 
which can stimulate the PKA pathway via the EP2 receptor. In 
addition to their direct pro-angiogenic action, PGs may also 
induce angiogenesis indirectly, via activating monocytes that 
infiltrate tumor tissues. Subsequently, the activated vascular 
COX-2 leads to the elevated permeability, proliferation, and 
morphogenesis of vasculatures.81 The high microvessel den-
sity results in the greater metastatic potential of tumor cells 
and poor patient prognosis.78,81 Furthermore, PGE2 can also 
promote angiogenesis through activating EP4 and its second 
messenger PKA in ECs.82
Celecoxib could inhibit PGE2-induced angiogenesis and 
lymphangiogenesis and sequentially inhibit tumor growth 
and metastasis, especially in COX-2-overexpressed cell 
lines,17,83 together with the reduction in microvessel density, 
microtubule formation, and serum VEGF level.84,85 This 
inhibition effect was associated with PGE2 receptor 4 (EP4) 
and could be reversed by exogenous PGE2.86 Microvascu-
lar permeability could also be reduced by celecoxib.87,88 
Tamoxifen (TAM) is an ER modulator and widely used in 
the treatment of BC as an adjuvant therapy against recurrence 
after surgery. Nevertheless, prolonged TAM administration 
increases VEGF levels in BC patients, stimulating new blood 
vessel formation and thus limiting its effectiveness. Kumar 
et al89 demonstrated that celecoxib can relieve TAM-induced 
angiogenesis via ROS-dependent VEGF/VEGFR2 autocrine 
signaling. In addition, Vaish and Sanyal90 reported that cele-
coxib can inhibit angiogenesis during the early neoplasm of 
colon through regulating PI3-K/PTEN/Akt and the canonical 
Wnt/β-catenin signaling pathway. In short, these findings 
shed light on molecular mechanisms underlying celecoxib’s 
anticancer effect from another perspective, which enhances 
the positive anticipation of its clinical application.
Integrating celecoxib into BC 
treatment
Celecoxib has been examined for improvement in chemo-
therapy effectiveness in cancer clinical trials. In fact, it has 
been reported that celecoxib could stimulate sensitivity to 
chemotherapy of BC cells91–93 via affecting the activation 
of multidrug resistance protein 1 (MDR1) which induces 
drug resistance and could be upregulated by COX-2.94,95 
Instead of affecting the pump function of MDR1, celecoxib 
downregulates its expression by inducing hypermethylation 
of MDR1 gene promoter96 and inhibiting the DNA-binding 
activity and expression of nuclear transcription factors such 
as AP-1 and NF-κB, which can combine with putative  binding 
sites of human MDR1 gene promoter.97 In addition to the 
activation of MDR1, of pertinence to this review, celecoxib 
was recently demonstrated to significantly sensitize other 
antitumor drugs with multiple mechanisms.
Combination with chemotherapy
Considering its own antitumor competence and resensitiza-
tion of other antitumor drugs, celecoxib could be a potential 
candidate for combination therapy. Preclinical research 
suggested that the antitumor effect of several agents can be 
enhanced by combining with celecoxib,98 including doxoru-
bicin99 and 5-fluorouracil (5-FU).100 In several Phase II stud-
ies, the combination of celecoxib and capecitabine, an orally 
administered pro-drug of 5-FU, could provide a clinical ben-
efit rate at 42.1–47.5% and an unexpected lower toxicity than 
capecitabine alone in metastatic BC (MBC) patients.101,102 In 
a single-arm, mono-institutional, nonrandomized, Phase II, 
two-step clinical trial, celecoxib was combined with cyclo-
phosphamide, and the clinical benefit of this combination 
came to 55% in 20 advanced BC (ABC) patients.103
Celecoxib can also be integrated into multidrug che-
motherapy regimens, in which FEC (5-FU, epirubicin, 
and cyclophosphamide) is the most common one. A study 
containing 50 patients showed that preoperative FEC with 
celecoxib (FECC) could provide lower intensity staining for 
COX-2, Ki-67, and p53 in 90% patients, while no difference 
was observed on tumor size, grade, or axillary lymph node 
status.104 In a Phase II, multicenter, open-label, single-arm 
study (N001),105 64 invasive BC patients received four cycles 
of FEC (500, 100, 500 mg/m2) followed by four cycles of 
docetaxel (100 mg/m2) with celecoxib (200 mg twice daily) as 
neoadjuvant therapy (NAT). After NAT, 43 patients achieved 
clinical complete response (cCR) and 13 achieved clinical 
partial response (cPR). In addition, despite potential side 
effects on cardiac system, the cardiac safety of celecoxib 
has been declared to be acceptable.106,107
It has also been reported that celecoxib increases the 
sensitivity of drug-resistant KBV20C cancer cells to anti-
mitotic drugs.108 This sensitization mechanism is indepen-
dent of the suppression of p-glycoprotein, indicating that 
the KBV20C cells are sensitized via targeting of signaling 
pathways by celecoxib. Moreover, it has also been observed 
that celecoxib intensely sensitizes KBV20C cells to vin-
blastine and paclitaxel, as indicated by microscopic obser-
vation, determination of Annexin V staining, and cleaved 
poly(ADP-ribose) polymerase (cleaved PARP). These 
results suggest that COX-2 inhibitors such as celecoxib 
can be used for cancer patients with potential resistance, 
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without the toxic effects of p-glycoprotein suppression. 
Of interest, as detailed previously,109 celecoxib promotes 
(sorafenib + sildenafil) lethality in multiple ovarian cancer 
cell lines, concomitant with a decrease in the expression of 
several chaperone proteins in parallel with decreased levels 
of the drug efflux pumps such as ABCB1/ABCG2. The cyto-
toxicity by the triple combination was induced by caspase 
9-dependent apoptotic pathway and RIP-1/caspases 2, 4/
AIF-dependent necroptotic pathway. In addition, the triple 
combination significantly reverted platinum chemotherapy 
resistance. Combined with the previous studies substantiat-
ing in vivo the combinations of “celecoxib + sildenafil” and 
“sorafenib + sildenafil” as cytotoxic to various cancer cell 
types, it has been suggested that the celecoxib/sorafenib/
sildenafil combination ought to be investigated in a Phase 
I trial in ovarian cancer.109 Table 1 summarizes the drugs 
suggested for use in combination with celecoxib for BC 
treatment based on preclinical data.
Not all the studies showed positive results, especially in 
patients with HER2-negative tumor. A multicenter random-
ized controlled Phase II clinical trial showed that celecoxib 
did not improve pathological complete response (pCR) rates 
in addition to epirubicin–cyclophosphamide–docetaxel (EC-
D) regimen.110 Moreover, the REMAGUS-02 multicenter 
randomized Phase II trial111 demonstrated that the addition of 
celecoxib could not provide an increased pCR rate in HER2-
negative patients. The long-term follow-up indicated that, in 
the HER2-negative subgroup, the addition of celecoxib led 
to smaller tumor size and lower expression of progesterone 
receptor (PgR) status, but no association of disease-free sur-
vival (DFS) benefit. In BC patients, COX-2 overexpression 
can be induced by HER2 oncogene activation112 and provide 
Table 1 Preclinical studies on combination of celecoxib and other therapeutic drugs in BC
Study Combination reagent Subject Mechanism of action
van wijngaarden 
et al99
Doxorubicin MDA-MB-231 cell line NF-κB-mediated increase in intracellular accumulation
irie et al100 5-FU BALB/c mice Suppression of veGF, enhancement of iFN-γ
Lim et al108 Paclitaxcel and vinblastine KB and KBv20C cell lines increasing G2 phase cell cycle arrest, C-PARP 
production
Hahn et al85 DC-based cell vaccines
GM-CSF
BALB/c mice (4T1) elevation of iFN-γ and iL-4 secretion by CD4+ T cells
Increased infiltration of CD4+ and CD8+ T cells
Basu et al128 Dendritic cell-based cancer 
vaccine
MMTv-Pyv MT mice Reduction in iDO and survivin
increasing PTeN, Bax, and iFN-γ-producing CD8+ 
CTLs
Li et al129 PD-1 mAb BALB/c mice (4T1) increasing CXCL9 and CXCL10
Suppression of iL-1, iL-6
Cho et al130 Nelfinavir (Viracept) MCF7, MCF7/Doxa, MCF7/Taxb
BT-474, BT-1.0B and BT-1.0ec
Aggravation of eR stress
Mustafa and 
Kruger133
F-l-Leu MMAC-1 cell line
C3 (1)-Sv40 Tag-transgenic mice
Activation of PTeN
Niu et al134 Minocycline hydrochloride Nude mice (MDA-MB-435S) inhibition of veGF and MMP-9
increasing tumor cell death
Yu et al135 Matrine MDA-MB-231 cell line impact on eGF/veGF-veGFR1-Akt-NF-κB signaling 
pathway
wang et al136 Berbamine MDA-MB-231 and MDA-MB-435S 
cell lines
inhibition of Akt, NF-κB target, c-Met, Bcl-2/Bax, 
osteopontin, veGF, MMP-9, and MMP-2
Jeon et al137 Luteolin MCF-7, MCF7/HeR18, MDA-
MB-231, and SkBr3 cell lines
BALB/c nude mice (MDA-MB-231)
in MCF-7 and MCF7/HeR18 cells: Akt inactivation and 
eRK signaling inhibition
in MDA-MB-231 and SkBr3 cells: Akt inactivation and 
eRK signaling activation
Kisková et al139 Resveratrol Sprague Dawley rats
MCF-7 cell line
inducing GDF15
Thill et al142 vitamin D MDA-MB-231 and MCF-7 cell 
lines
Suppression of aromatase expression
Notes: aMCF7/Dox, a doxorubicin/multidrug-resistant variant of MCF7. bMCF7/Tax, a taxol-resistant variant of MCF7. cBT-1.0B and BT-1.0e, two trastuzumab-resistant 
variants of BT474.
Abbreviations: BC, breast cancer; CTLs, cytotoxic T cells; CXCL, C–X–C motif ligand; DC, dendritic cell; eR, estrogen receptor; F-l-Leu, N-(9-fluorenyl-methyloxycarbonyl)-
l-leucine; 5-FU, fluorouracil; GDF, growth differentiation factor; GM-CSF, granulocyte–macrophage colony-stimulating factor; IDO, indoleamine 2,3-dioxygenase; IFN, 
interferon; iL, interleukin; MMAC, mammary adenocarcinoma cell; MMP, matrix metalloproteinase; PARP, poly(ADP-ribose) polymerase; PD-1 mAb, programmed death 1 
monoclonal antibody; veGF, vascular endothelial growth factor.
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a positive feedback through its product PGE2 which induces 
HER2 expression.113 However, the combination of celecoxib 
(400 mg twice daily) and trastuzumab (2 mg/kg intravenous 
injection weekly or 6 mg/kg intravenous injection every 
3 weeks) provided no significant enhancement in a Phase II 
study.114 Of note, El-Awady et al115 explored the ability of 
celecoxib to sensitize different types of cancer cells (HeLa, 
HCT116, HepG2, MCF-7, and U251) to a number of anti-
cancer drugs (5-FU, cisplatin, doxorubicin, and etoposide). 
Interaction of celecoxib with these chemotherapeutic drugs 
is antagonistic in the BC cells, MCF-7, but not in other cells, 
suggesting that celecoxib exerts distinct molecular actions 
in different cancer cells. Mechanistic investigations demon-
strated that celecoxib increases drug-triggered G2/M arrest 
in MCF-7 cells allowing more time to repair drug-elicited 
DNA damage before access into mitosis, leading to decrease 
in cell death and thus contributing to antagonism. These find-
ings, if substantiated in vivo, suggest that celecoxib is not an 
appropriate chemo-sensitizer for BC. Therefore, the combina-
tion of celecoxib with other chemotherapeutic drugs must 
be customized to the cancer type. To obtain a more accurate 
conclusion, more in-depth and extensive clinical trials are 
Table 2 Clinical trials of celecoxib on BC (ClinicalTrial.gov)
NCT number Phase Start date Status Patients Enrollment Interventions
NCT00075673 i November 2003 Terminated with recurrent or 
metastatic (stage iv) disease
6 Celecoxib on days 1–21, repeat 
every 21 days
vinorelbine ditartrate on days 7, 14, 
and 21, repeat every 21 days
NCT01425476 i/ii July 2008 Completed with increased risk of BC 45 Celecoxib
Cholecalciferol 400 iU or 2,000 iU/
daily for 30 days
NCT00201773 ii July 2003 Completed with stage ii–iv disease 22 exemestane 25 mg QD for 16 weeks
Celecoxib 200 mg BiD for 16 weeks
NCT00291694 ii April 2003 Completed with increased risk of BC 72 Celecoxib 400 mg BiD for 12 months
Placebo
NCT00056082 ii January 2003 Completed with increased risk of BC 110 Celecoxib 400 mg BiD for 12 months
NCT00291122 – January 2003 Completed with T1 or T2 noninvasive 
BC
100 Celecoxib 400 mg BiD
NCT00070057 i April 2009 Completed 75 Celecoxib for 1–3 weeks
Celecoxib (the doses are higher 
than those of the aforementioned 
studies) for 1–3 weeks
No intervention
NCT01769625 i/ii January 2009 Completed with invasive breast 
carcinoma (≥1 cm)
31 Placebo + cholecalciferol 400 iU
Placebo + cholecalciferol 2,000 iU
Celecoxib 400 mg + cholecalciferol 
400 iU
Celecoxib 400 mg + cholecalciferol 
2,000 iU
NCT03185871 ii September 2017 Recruiting with stages T1cN0 to 
T3N0 BC (≥1 cm), eR/PgR 
(+), without lymph node 
spread
45 Celecoxib 200 mg BiD for 2 weeks
NCT01881048 i December 2009 Active, not 
recruiting
with BC 42 No intervention
Omega-3 fatty
Celecoxib
NCT00045591 ii February 2003 Terminated with invasive BC 39 Celecoxib 100 mg BiD
Celecoxib 400 mg BiD
NCT00088972 ii November 2004 Terminated with increased risk of BC 8 Celecoxib
Placebo
NCT00328432 i June 2003 Completed with T1 or T2 noninvasive 
breast
100 Celecoxib 400 mg BiD
NCT00305643 iii February 2003 Terminated with metastatic colorectal 
cancer or MBC
11 Celecoxib 200 mg BiD + standard 
capecitabine treatment
Placebo with standard capecitabine 
treatment
Abbreviations: BC, breast cancer; eR, estrogen receptor; MBC, metastatic BC; PgR, progesterone receptor; BiD, twice a day; QD, once a day.
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needed. Table 2 summarizes the clinical trials of celecoxib 
or celecoxib combined with chemotherapy on BC patients.
Combination with endocrinal therapy
It was demonstrated that the expression of aromatase CYP19 
might be potentially regulated by PGE2 through cAMP-
mediated pathways, and it makes further influence on aroma-
tase activity116,117 and estrogen biosynthesis.69 Linear positive 
correlation was shown between CYP19 and COX-2 by semi-
quantitative reverse transcriptase PCR (RT-PCR), suggesting 
that the combination of COX-2 and aromatase inhibitors (AIs) 
could have synergistic effect on hormone-dependent BC.69 
The inhibition of aromatase by celecoxib was observed at 
transcriptional level by real-time PCR and appeared to be 
dose dependent.118 Anastrozole, an AI, was combined with 
celecoxib to treat BC in rats.119 The results showed that this 
combination might be workable for clinical therapy.
Besides laboratory investigations, clinical trials also 
conducted to combine celecoxib with selective ER modula-
tor (TAM) and AIs (exemestane). In the Celecoxib Anti-
Aromatase Neoadjuvant (CAAN) trial,120 a combination of 
exemestane (25 mg daily) and celecoxib (400 mg twice daily) 
gained significantly lowered cholesterol and low-density lipo-
protein (LDL) levels and higher bone mineral density (BMD) 
and BC subscale scores compared with single-agent groups 
of exemestane (25 mg daily) and letrozole (2.5 mg daily), in 
postmenopausal women with histologically proven local ABC 
(LABC). So, although the final outcomes showed no statistical 
difference on clinical response and tumor volume,121 which 
meant that different neoadjuvant anti-aromatase therapies have 
similar efficacy, the combination with celecoxib may provide 
some additional benefits. Some other studies, including a Phase 
II study122 and a Phase III study,123 positively supported the 
combination of celecoxib and exemestane in postmenopausal 
MBC patients. A Phase II trial of neoadjuvant exemestane (25 
mg daily) plus celecoxib (400 mg twice daily) demonstrated 
that the combination was tolerated and anticancer response was 
observed in the majority of postmenopausal women with BC. 
Statistically, noteworthy reduction could also be found in the 
expression of ER, PgR, Ki-67, and COX-2.124 Nevertheless, 
some other research provided a different opinion. A study 
established by Dirix et al125 showed that the demographic 
characteristics, prognostic factors, and time to progression 
(TTP) were all similar no matter whether celecoxib was added 
to endocrine therapy or not, and the lack of COX-2 expression 
may attribute to this result.126 Moreover, it was suggested that 
the anticancer effect of combination therapy might have mainly 
resulted from exemestane instead of celecoxib.127
TAM is extensively used in BC therapy as a preventive 
drug against recurrence after surgical treatment, but the long-
term TAM treatment enhances patients’ VEGF levels, stimu-
lates neovascularization, and thus restrains its effectiveness. 
Kumar et al89 demonstrated that the combination of TAM and 
celecoxib at nontoxic concentrations exerted antiangiogenic 
effects via explicitly targeting VEGF–VEGFR2 pathway 
through ROS formation. In addition, their preclinical studies 
suggested that the TAM/celecoxib combination is a feasible 
strategy for the treatment of BCs with VEGF/VEGFR2 over-
expression. This inventive combination exhibits encouraging 
effect in anti-metastasis and stimulation of apoptosis and may 
be a superior personalized clinical regimen vs TAM alone 
for BC treatment. The clinical trials on the combination of 
endocrine therapy and celecoxib are summarized in Table 3.
Combination with other antitumor 
treatments
Dendritic cell-based cancer vaccine, from tumor lysate-pulsed 
dendritic cell, is a popular candidate for cancer immunother-
apy. Hahn et al85 tested the antitumor immune response using 
the combination of celecoxib, vaccine, and GM-CSF in 4T1 
cells, a cell line with COX-2 expression, poorly immunogenic, 
and highly metastatic ability. The triple combination therapy 
successfully suppressed primary tumor growth and signifi-
cantly reduced the incidence of lung metastases. This effect 
was achieved by a tumor-specific immune response which 
could be observed as increased interferon (IFN)-γ and IL-4 
secretion by CD4+ T cells and infiltration of CD4+ and CD8+ 
T cells to the tumor site. Basu et al128 also combined celecoxib 
with dendritic cell-based cancer vaccine and reconfirmed that 
the combination gained its antitumor effect by downregulat-
ing the expression of indoleamine 2,3-dioxygenase (IDO), a 
negative regulator of T cell activity. A recent study by Li et 
al129 using alginate hydrogel system to locally deliver cele-
coxib and programmed death 1 (PD-1) monoclonal antibody 
(mAb) to treat 4T1 MBC mouse model demonstrated a sig-
nificant improvement in the anticancer activities of celecoxib, 
PD-1 mAb, or both combined. The persistent high levels of 
the drugs in peripheral circulation and within local tumor 
areas were observed. Importantly, the concurrent dual local 
delivery of celecoxib and PD-1 synergistically elevated the 
levels of CD4+ IFN-γ+/CD8+ IFN-γ+ T cells in the tumor and 
the immune system, implying that the combinatorial therapy 
synergistically enhances antitumor immunity. In addition, 
this combination treatment induces the production of two 
antiangiogenic chemokines such as C–X–C motif ligand 
(CXCL)9 and CXCL10 as well as inhibits the intra-tumoral 
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formation of IL-1, IL-6, and COX2, indicating a diminished 
pro-cancer angiogenic and inflammatory microenvironment. 
This celecoxib/PD-1 mAb combination treatment provides a 
promising regimen for treating human BC.
By combining celecoxib with the HIV protease inhibitor, 
nelfinavir (Viracept), Cho et al130 explored the aggravation 
of endoplasmic reticulum stress caused by this combination, 
which led to apoptosis in chemoresistant BC cells. Further-
more, unmethylated celecoxib (UMC), with superior COX-2 
inhibitory efficacy, showed substantially weaker antitumor 
effect. Therefore, they speculated that the antitumor effect 
of celecoxib was COX-2 independent in chemoresistant 
BC. Chloroquine is another material that can play a role 
in antitumor effect with celecoxib through endoplasmic 
reticulum stress response.131 In addition, treatment with the 
combination of anti-IL-17 antibody and celecoxib can sig-
nificantly decrease bone and lung metastasis in SKG mice 
with mammary gland tumors and autoimmune arthritis.132 
Preclinical studies also suggested that celecoxib could be 
combined with peroxisome proliferator-activated receptor 
gamma agonist for the treatment of spontaneous BC133 and 
minocycline hydrochloride for osseous metastasis in BC.134 
These combination treatments were strikingly more effective 
than celecoxib alone. Moreover, many plant-derived materials 
were combined with celecoxib and emerged synergistic effect 
on antitumor effect via VEGF/Akt/NF-κB signaling, includ-
ing matrine,135 berbamine,136 and luteolin.137,138 Resveratrol139 
can also enhance the tumor prevention effect of celecoxib, 
but the exact mechanism is still under investigated.
Several epidemiological studies have shown that vitamin 
D has beneficial effects against the carcinogenesis and devel-
opment of BC.140,141 Recent studies revealed an association 
between vitamin D and PGE2 metabolism. Thill et al142 
demonstrated that a synergistic growth-inhibiting effect in BC 
cell lines can be elicited by the combination of celecoxib and 
calcitriol (1,25-dihydroxycholecalciferol or 1,25-[OH]2D3), 
which is a biologically active form of vitamin D.143 Calcitriol 
could also inhibit COX-2 expression at both protein and 
mRNA levels. New perspectives emerge from the growing 
knowledge of innovative combination of celecoxib, and 
other anticancer agents, which act in a complementary way, 
increase the efficacy and minimize toxicity.
Side effects and clinical complications
Celecoxib is the only FDA-approved COX-2 inhibitor for use 
in the USA. Although celecoxib is usually a well-tolerated 
drug, it is not harmless. Its typical doses range from 200 to 
400 mg/day; nonetheless, the dose for acute gout can reach 
800 mg once, followed by 400 mg on the first day, then 400 
mg twice daily for 7 days. A higher dose of celecoxib (800 
mg per day) might be related to augmented cardiovascular 
risk according to the Adenoma Prevention with Celecoxib 
(APC) study.144 The cardiotoxicity side effects may be attrib-
uted to its off-target effect, namely modulating calcium levels 
within the cell, according to the immediate time-dependent 
cell response profiles (TCRPs) for celecoxib.145 In fact, 
previous studies have shown that celecoxib therapy induces 
an immediate increase in intracellular calcium levels.146 In 
addition, clinical data indicate that chronic use of celecoxib 
may damage normal skeletal function resulting in reduced 
BMD in older male patients.147 Serious allergic reactions to 
celecoxib have also been reported.148
When celecoxib is recommended in advanced cancer 
patients, the pros and cons need to be considered prudently. 
A meta-analysis by Chen et al149 suggested that celecoxib has 
certain benefits in the treatment of cancer, but increases the 
risk of cardiovascular events. Specifically, they demonstrated 
an increase in grade 3 and 4 toxicities of cardiovascular 
events with the incorporation of celecoxib to the treatment 
of advanced cancers. Other toxicities include rash, hepato-
toxicity, and gastrointestinal events, and there is no statisti-
cally significant difference among them. Of note, the risk of 
anemia in the celecoxib group is also significant. Although 
the risk of grade 3 and 4 cardiovascular events increases by 
1.78 times after celecoxib use for a long time, the risk is 
acceptable, considering that this is a prescription for life-
threatening diseases. Nevertheless, clinical monitoring of 
side effects, for example, cardiovascular events should be 
strengthened. According to these findings, it is necessary to 
carefully consider the benefit vs harm when recommending 
celecoxib in the treatment of patients with advanced cancer, 
especially those with a history of heart disease. Further stud-
ies are needed to confirm these results with large samples.
Conclusion
In addition to being widely used for treating inflammatory 
diseases such as rheumatoid arthritis and osteoarthritis,150 
celecoxib may also play an important role in the cancer 
prevention and treatment. Preclinical evidence demonstrates 
that celecoxib seems to suppress the proliferation and growth 
of different types of cancer through various mechanisms 
(Figure 1). Results of abundant clinical studies, although 
unconvincing, suggest that celecoxib administration is related 
not only to diminished incidence of cancer but also to the 
better prognosis in cancer patients. In view of the potential 
variations in response to celecoxib in cancer patients, it 
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seems critical to ascertain target populations for its use. 
Nevertheless, factors that contribute to better outcome in 
celecoxib consumers are still to be explicated. The data on 
the effectiveness of celecoxib as neoadjuvant treatment in 
cancer patients are deficient. There are substantial clinical 
studies evaluating the role of celecoxib in the cancer treat-
ment. The results will permit evaluation of the position of 
celecoxib in cancer prevention and therapy and identify the 
target populations in the near future. Of note, comparative 
studies should be designed to ascertain the optimal dosage, 
duration, side effects (especially the gastrointestinal and 
cardiovascular systems), and its cost-effectiveness. As was 
originally pointed out more than 10 years ago, “there exists 
an urgent need for clinical trials of this compound so as to 
accelerate its effective application in the chemoprevention 
and treatment of cancer.” NSAIDs, and especially celecoxib, 
represent an inspiring proposition for repurposing as anti-
cancer drugs with low toxicity, hence demonstrating how 
understanding cancer-relevant molecular signaling pathways 
in combination with clinical data will contribute to further 
development of oncology.
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